CD36 and atherosclerosis: The authors found that administration of C1q/tumour necrosis factor-related protein 13 (CTRP13) reduced CD36 expression in vitro and significantly reduced aortic atherosclerosis in vivo, thus defining a potential novel therapeutic in atherosclerosis by SR modulation.